|Bid||6.02 x 900|
|Ask||6.15 x 1200|
|Day's range||5.61 - 6.08|
|52-week range||4.56 - 39.41|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
New cancer trial results from the clinical-stage biopharmaceutical company inspired a juicy buyout offer.